Galena public offering raises $14.5M to support NeuVax studies
This article was originally published in Scrip
Executive Summary
Galena Biopharma, a US oncology-focused company, said that it has closed on its underwritten public offering for gross proceeds of about $14.5 million. consisted of 9.75 million shares of its common stock at $1.50 per share,.